TY - JOUR
T1 - Participation of people living with disabilities in physical activity: a global perspective
AU - Martin Ginis, Kathleen A.
AU - van der Ploeg, Hidde P.
AU - Foster, Charlie
AU - Lai, Byron
AU - McBride, Christopher B.
AU - Ng, Kwok
AU - Pratt, Michael
AU - Shirazipour, Celina H.
AU - Smith, Brett
AU - Vásquez, Priscilla M.
AU - Heath, Gregory W.
N1 - Funding Information: We gratefully acknowledge research and administrative support from Gabriel Dix, Sarah Lawrason, Zachary North, Ritu Sharma, and Adrienne Sinden. KAMG holds the Reichwald Family Southern Medical Program Chair in Preventive Medicine. GWH is in receipt of a US National Institutes of Health grant that is unrelated to this manuscript (NIH 3R15GM131315-01A1S1). Editorial note: the Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations. Publisher Copyright: © 2021 Elsevier Ltd Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/7/31
Y1 - 2021/7/31
N2 - Approximately 1·5 billion people worldwide live with a physical, mental, sensory, or intellectual disability, about 80% of which are in low-income and middle-income countries. This Series paper provides a global overview of the prevalence, benefits, and promotion policies for physical activity for people living with disabilities (PLWD). PLWD are 16–62% less likely to meet physical activity guidelines and are at higher risk of serious health problems related to inactivity than people without disabilities. Meta-analyses have shown that physical activity has beneficial effects on cardiovascular fitness (average standardised mean difference [SMD] 0·69 [95% CI 0·31–1·01]), musculoskeletal fitness (0·59 [0·31–0·87]), cardiometabolic risk factors (0·39 [0·04–0·75]), and brain and mental health outcomes (0·47 [0·21–0·73]). These meta-analyses also show that health benefits can be achieved even with less than 150 min of physical activity per week, and suggest that some physical activity is better than none. Meta-analyses of interventions to increase physical activity for PLWD have reported effect sizes ranging from SMD 0·29 (95% CI 0·17–0·41, k=10) to 1·00 (0·46–1·53, k=10). There is increasing awareness among policy makers of the needs of PLWD for full participation in physical activity. Physical activity action plans worldwide must be adequately resourced, monitored, and enforced to truly advance the fundamental rights of PLWD to fully participate in physical activity.
AB - Approximately 1·5 billion people worldwide live with a physical, mental, sensory, or intellectual disability, about 80% of which are in low-income and middle-income countries. This Series paper provides a global overview of the prevalence, benefits, and promotion policies for physical activity for people living with disabilities (PLWD). PLWD are 16–62% less likely to meet physical activity guidelines and are at higher risk of serious health problems related to inactivity than people without disabilities. Meta-analyses have shown that physical activity has beneficial effects on cardiovascular fitness (average standardised mean difference [SMD] 0·69 [95% CI 0·31–1·01]), musculoskeletal fitness (0·59 [0·31–0·87]), cardiometabolic risk factors (0·39 [0·04–0·75]), and brain and mental health outcomes (0·47 [0·21–0·73]). These meta-analyses also show that health benefits can be achieved even with less than 150 min of physical activity per week, and suggest that some physical activity is better than none. Meta-analyses of interventions to increase physical activity for PLWD have reported effect sizes ranging from SMD 0·29 (95% CI 0·17–0·41, k=10) to 1·00 (0·46–1·53, k=10). There is increasing awareness among policy makers of the needs of PLWD for full participation in physical activity. Physical activity action plans worldwide must be adequately resourced, monitored, and enforced to truly advance the fundamental rights of PLWD to fully participate in physical activity.
UR - http://www.scopus.com/inward/record.url?scp=85111342221&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/S0140-6736(21)01164-8
DO - https://doi.org/10.1016/S0140-6736(21)01164-8
M3 - Review article
SN - 0140-6736
VL - 398
SP - 443
EP - 455
JO - The Lancet
JF - The Lancet
IS - 10298
ER -